Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia

被引：20

作者：

Cazzaniga, Giovanni ^{[2
]}

Valsecchi, Maria Grazia ^{[3
]}

Gaipa, Giuseppe ^{[2
]}

Conter, Valentino ^{[1
,4
]}

Biondi, Andrea ^{[1
]}

机构：

[1] Univ Milano Bicocca, Dept Paediat, San Gerardo Hosp, Fdn MBBM,Paediatr Clin, I-20900 Monza, Italy

[2] Univ Milano Bicocca, San Gerardo Hosp, Paediat Clin, M Tettamanti Res Ctr, I-20900 Monza, Italy

[3] Univ Milano Bicocca, Ctr Biostat Clin Epidemiol, Dept Clin Med & Prevent, I-20900 Monza, Italy

[4] Osped Riuniti Bergamo, Dept Paediat, I-24100 Bergamo, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2011年 / 155卷 / 01期

关键词：

acute lymphoblastic leukaemia; minimal residual disease; prognostic factors; TIME QUANTITATIVE PCR; STEM-CELL TRANSPLANTATION; TREATMENT RESPONSE; PROGNOSTIC-SIGNIFICANCE; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; RISK CLASSIFICATION; POWERFUL PREDICTOR; MOLECULAR RESPONSE; FLOW-CYTOMETRY;

D O I：

10.1111/j.1365-2141.2011.08795.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Minimal residual disease (MRD) has acquired a prominent role in the management of childhood and adult Acute Lymphoblastic Leukaemia (ALL) for its high prognostic value. Several studies have demonstrated the strong association between MRD and risk of relapse in childhood and adult ALL, irrespective of the methodology used. MRD is now used in clinical trials for risk assignment and to guide clinical management. Negativity at early time points may be considered to decrease treatment burden in patients who are likely to be cured with reduced intensity regimens. On the other hand, high MRD levels at late time points (end of consolidation) define ALL subgroups which deserve investigation of more effective treatments. The predictivity of MRD as a measurement of drug response in vivo opened new perspectives for its use in clinical decision, to deliver risk-based treatments, and possibly as a surrogate for efficacy in the evaluation of novel therapeutic approaches.

引用

页码：45 / 52

页数：8

共 59 条

[1] Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials [J].

Attarbaschi, Andishe ;

Mann, Georg ;

Panzer-Gruemayer, Renate ;

Roettgers, Silja ;

Steiner, Manuel ;

Koenig, Margit ;

Csinady, Eva ;

Dworzak, Michael N. ;

Seidel, Markus ;

Janousek, Dasa ;

Moericke, Anja ;

Reichelt, Carsten ;

Harbott, Jochen ;

Schrappe, Martin ;

Gadner, Helmut ;

Haas, Oskar A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :3046-3050

[2] Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].

Bader, P ;

Hancock, J ;

Kreyenberg, H ;

Goulden, NJ ;

Niethammer, D ;

Oakhill, A ;

Steward, CG ;

Handgretinger, R ;

Beck, JF ;

Klingebiel, T .

LEUKEMIA, 2002, 16 (09) :1668-1672

[3] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group [J].

Bader, Peter ;

Kreyenberg, Hermann ;

Henze, Guenter H. R. ;

Eckert, Cornelia ;

Reising, Miriam ;

Willasch, Andre ;

Barth, Andrea ;

Borkhardt, Arndt ;

Peters, Christina ;

Handgretinger, Rupert ;

Sykora, Karl-Walter ;

Holter, Wolfgang ;

Kabisch, Hartmut ;

Klingebiel, Thomas ;

von Stackelberg, Arend .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :377-384

[4] Modern Therapy of Acute Lymphoblastic Leukemia [J].

Bassan, Renato ;

Hoelzer, Dieter .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :532-543

[5] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J].

Bassan, Renato ;

Spinelli, Orietta ;

Oldani, Elena ;

Intermesoli, Tamara ;

Tosi, Manuela ;

Peruta, Barbara ;

Rossi, Giuseppe ;

Borlenghi, Erika ;

Pogliani, Enrico M. ;

Terruzzi, Elisabetta ;

Fabris, Pietro ;

Cassibba, Vincenzo ;

Lambertenghi-Deliliers, Giorgio ;

Cortelezzi, Agostino ;

Bosi, Alberto ;

Gianfaldoni, Giacomo ;

Ciceri, Fabio ;

Bernardi, Massimo ;

Gallamini, Andrea ;

Mattei, Daniele ;

Di Bona, Eros ;

Romani, Claudio ;

Scattolin, Anna Maria ;

Barbui, Tiziano ;

Rambaldi, Alessandro .

BLOOD, 2009, 113 (18) :4153-4162

[6] Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow [J].

Basso, Giuseppe ;

Veltroni, Marinella ;

Valsecchi, Maria Grazia ;

Dworzak, Michael N. ;

Ratei, Richard ;

Silvestri, Daniela ;

Benetello, Alessandra ;

Buldini, Barbara ;

Maglia, Oscar ;

Masera, Giuseppe ;

Conter, Valentino ;

Arico, Maurizio ;

Biondi, Andrea ;

Gaipa, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5168-5174

[7] Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's oncology group study on behalf of the Dutch Childhood Oncology Group and the German Cooperative Study Group for childhood acute lymphoblastic leukemia [J].

Bhojwani, Deepa ;

Kang, Huining ;

Menezes, Renee X. ;

Yang, Wenjian ;

Sather, Harland ;

Moskowitz, Naomi P. ;

Min, Dong-Joon ;

Potter, Jeffrey W. ;

Harvey, Richard ;

Hunger, Stephen P. ;

Seibel, Nita ;

Raetz, Elizabeth A. ;

Pieters, Rob ;

Horstmann, Martin A. ;

Relling, Mary V. ;

den Boer, Monique L. ;

Willman, Cheryl L. ;

Carroll, William L. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) :4376-4384

[8]

Biondi A, 2008, BLOOD, V112, P537

[9] Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group [J].

Borowitz, MJ ;

Pullen, DJ ;

Winick, N ;

Martin, PL ;

Bowman, WP ;

Camitta, B .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2005, 68B (01) :18-24

[10] Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing [J].

Boyd, Scott D. ;

Marshall, Eleanor L. ;

Merker, Jason D. ;

Maniar, Jay M. ;

Zhang, Lyndon N. ;

Sahaf, Bita ;

Jones, Carol D. ;

Simen, Birgitte B. ;

Hanczaruk, Bozena ;

Nguyen, Khoa D. ;

Nadeau, Kari C. ;

Egholm, Michael ;

Miklos, David B. ;

Zehnder, James L. ;

Fire, Andrew Z. .

SCIENCE TRANSLATIONAL MEDICINE, 2009, 1 (12)

← 1 2 3 4 5 6 →